UCB SA (UCB.BR)

Company Profile

UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,083 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

Company Info

UCB SA

Allee de la Recherche, 60

Anderlecht BRUXELLES-CAPITALE

P: 3225599999

Employees: 9000

Website: https://www.ucb.com